Suppr超能文献

初发和既往存在的炎症性肠病对原位肝移植结局的影响。

Impact of De Novo and Preexisting Inflammatory Bowel Disease on the Outcome of Orthotopic Liver Transplantation.

作者信息

Kochhar Gursimran, Singh Tavankit, Dust Henry, Lopez Rocio, McCullough Arthur J, Liu Xiuli, Fung John, Shen Bo

机构信息

*Department of Gastroenterology and Hepatology, Digestive Disease Institute, Cleveland Clinic Foundation, Cleveland, Ohio; Departments of †Internal Medicine, ‡Quantitative Health Sciences, and §Anatomic Pathology, Cleveland Clinic Foundation, Cleveland, Ohio; and ¶Transplant Center, Cleveland Clinic Foundation, Cleveland, Ohio.

出版信息

Inflamm Bowel Dis. 2016 Jul;22(7):1670-8. doi: 10.1097/MIB.0000000000000830.

Abstract

BACKGROUND

Diarrhea is a common problem in the setting of solid-organ transplantation, especially orthotopic liver transplant (OLT). De novo or preexisting inflammatory bowel disease (IBD) is one of the differential diagnoses. The aims of our study were to evaluate the frequency of de novo IBD in patients with OLT and to assess the impact of de novo IBD and preexisting IBD on the outcome of OLT.

METHODS

This case-control study included all eligible patients who had OLT from January 2001 to December 2009. The study group included all patients who had a biopsy-proven diagnosis of IBD after their OLT (the de novo IBD group). The control groups included patients with existing IBD before OLT and those without IBD before and after OLT. The groups were matched based on their underlying diagnoses of end-stage liver disease. Univariate and multivariate analyses were performed.

RESULTS

A total of 66 subjects were included in the study. The mean age was 45.4 ± 13.4 years, with 44 (66.7%) being male. Fifteen patients (23%) had de novo IBD, 21 (32%) had existing IBD before OLT, and 30 (45%) had no underlying IBD before or after OLT. There were no significant differences between the 2 IBD groups in any of the IBD characteristics, including IBD medications. Subjects without IBD were more likely to receive mycophenolate mofetil within 1 week of OLT than those in the de novo or preexisting IBD (70% versus 23% P = 0.018). Episodes of graft rejection were more commonly observed in subjects with preexisting IBD (52%) than de novo IBD (27%) or no IBD (20%) (P = 0.045). The rate of retransplantation was highest in the de novo IBD group followed by the preexisting IBD group and non-IBD group (20% versus 14% versus 0%; P = 0.029). Combined together, patients with IBD in the setting of OLT were more likely to be retransplanted than those without IBD (16.7% versus 0%, P = 0.045). In multivariate analysis, we found that patients with IBD were 6.7 (95% confidence interval, 1.9-23.9) times more likely to have an adverse outcome after liver transplant (P = 0.004), after adjusting for primary sclerosing cholangitis.

CONCLUSIONS

De novo IBD can occur in patients after OLT. De novo IBD and preexisting IBD were found to be associated with a higher risk for graft failure, suggesting that early diagnosis and closer monitoring of the patients at risk are critical.

摘要

背景

腹泻是实体器官移植,尤其是原位肝移植(OLT)中常见的问题。新发或既往存在的炎症性肠病(IBD)是鉴别诊断之一。我们研究的目的是评估OLT患者中新发IBD的发生率,并评估新发IBD和既往存在的IBD对OLT结局的影响。

方法

本病例对照研究纳入了2001年1月至2009年12月期间所有接受OLT的符合条件的患者。研究组包括所有OLT术后经活检证实诊断为IBD的患者(新发IBD组)。对照组包括OLT术前存在IBD的患者以及OLT术前术后均无IBD的患者。根据终末期肝病的基础诊断对各组进行匹配。进行了单因素和多因素分析。

结果

本研究共纳入66名受试者。平均年龄为45.4±13.4岁,其中44名(66.7%)为男性。15名患者(23%)新发IBD,21名(32%)OLT术前存在IBD,30名(45%)OLT术前术后均无基础IBD。在任何IBD特征(包括IBD用药)方面,两个IBD组之间均无显著差异。无IBD的受试者比新发或既往存在IBD的受试者在OLT后1周内更有可能接受霉酚酸酯治疗(70%对23%,P = 0.018)。既往存在IBD的受试者(52%)比新发IBD(27%)或无IBD(20%)的受试者更常出现移植排斥反应(P = 0.045)。再次移植率在新发IBD组最高,其次是既往存在IBD组和无IBD组(20%对14%对0%;P = 0.029)。综合来看,OLT患者中患有IBD的患者比无IBD的患者更有可能接受再次移植(16.7%对0%,P = 0.045)。在多因素分析中,我们发现,在调整原发性硬化性胆管炎后,IBD患者肝移植后出现不良结局的可能性高6.7倍(95%置信区间,1.9 - 23.9)(P = 0.004)。

结论

新发IBD可发生在OLT术后患者中。发现新发IBD和既往存在的IBD与移植失败风险较高相关,这表明对有风险的患者进行早期诊断和密切监测至关重要。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验